The Japanese Pharmaceuticals and Medical Devices Agency has cleared the latest version of CathWork's FFRangio System for diagnosing functional ischemia in patients with ischemic coronary artery disease.
The fourth-generation system includes significant automation and enhancements while offering the same 93% diagnostic accuracy for measuring fractional flow reserve (FFR) compared with invasive wire-derived FFR, according to the company.
